Bifidobacterium animalis subsp. Lactis C-2 with effect of improving inflammatory bowel disease and application of bifidobacterium animalis subsp. Lactis C-2

Abstract

The invention relates to bifidobacterium animalis subsp. Lactis C-2 with an effect of improving inflammatory bowel diseases and application of the bifidobacterium animalis subsp. Lactis C-2. The bifidobacterium animalis subsp. Lactis C-2 is classified and named as Bifidobacterium animalis subsp. Lactis, and the preservation number of the bifidobacterium animalis subsp. Lactis C-2 is GDMCC No: 65455. The bacterial strain can inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria and optimize the composition of intestinal microorganisms by regulating the intestinal microecology, repairing the intestinal mechanical barrier, improving the intestinal immune response, inhibiting oxidative stress reaction and other action mechanisms, thereby inducing anti-inflammatory response and improving the intestinal barrier function. Therefore, the bifidobacterium animalis subsp. Lactis C-2 strain is suitable for preparing the medicine with the effect of preventing, improving or treating the inflammatory bowel disease.

Description

Technical Field

[0001] The invention belongs to the technical field of microbial culture, and relates to animal Bifidobacterium lactis subspecies C-2 with efficacy of improving inflammatory bowel disease and application thereof. Background Art

[0002] Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that affects the ileum, rectum, and colon, including ulcerative colitis (UC) and Crohn's disease (CD). Their clinical manifestations usually include abdominal pain, diarrhea, and bloody stools, which can lead to complications such as gastrointestinal perforation and bleeding in severe cases. The pathogenesis of IBD has not yet been fully clarified, but existing studies have revealed that multiple factors may play an important role in its occurrence and progression. Modern third-generation sequencing technology has revealed that the diversity and richness of the intestinal flora of IBD patients are low, the number of beneficial bacteria is reduced, and the number of pathogenic bacteria is increased. These microbial imbalances trigger the overproduction of lipopolysaccharide, which in turn activates the intestinal inflammatory signaling pathway and promotes the development of inflammatory response. The destruction of intestinal barrier function is also an important link in the pathogenesis of IBD. Under normal circumstances, the intestinal barrier can effectively isolate harmful substances and pathogenic microorganisms in the intestine, but IBD patients often have a destruction of the intestinal barrier function, resulting in excessive intestinal immune response. The metabolites of the intestinal flora, such as short-chain fatty acids, can maintain the integrity of the intestinal barrier and support the balance of the immune system. The reduction of these beneficial metabolites in IBD patients results in insufficient nutrient supply to intestinal epithelial cells and abnormal immune function, further exacerbating intestinal inflammation.

[0003] Current IBD treatments rely mainly on drug therapy, including aminosalicylates, corticosteroids, immunosuppressants, and biologics. Aminosalicylates (such as mesalazine) are effective in controlling mild to moderate active disease, but the effect is general and can only relieve related symptoms; corticosteroids can be used to control acute attacks, but long-term use may cause side effects such as osteoporosis and diabetes; long-term use of immunosuppressants (such as azathioprine and cyclophosphamide) will also increase the risk of infection; biologics, especially tumor necrosis factor (TNF) specific inhibitors (such as infliximab and adalimumab), have become an important means of treating IBD, but some patients develop resistance or non-response to biologics. Therefore, exploring new treatment strategies has become an urgent need.

[0004] Probiotics are defined as "live microorganisms" that, when ingested in sufficient amounts, can have a health impact on the host. The intestinal tract is the most important organ for the digestion and absorption of nutrients, and its health level determines the overall health of the body. Probiotics can play a potential role in the prevention and treatment of ulcerative colitis by improving intestinal barrier function, regulating the structure of intestinal flora, and inhibiting the growth of harmful bacteria. Therefore, how to provide an efficient microbial preparation containing probiotics that can be used to improve inflammatory bowel disease and promote intestinal health has become a technical problem that needs to be solved urgently. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide an animal Bifidobacterium lactis subspecies C-2 having the efficacy of improving inflammatory bowel disease and its application.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions: In a first aspect, the present invention provides an animal Bifidobacterium lactis subspecies C-2 having the efficacy of improving inflammatory bowel disease, wherein the classification of the animal Bifidobacterium lactis subspecies C-2 is named Bifidobacterium animalis subsp. lactis , the deposit number is GDMCC No: 65455, and the deposit date is November 8, 2024.

[0007] The present invention separates and preserves a new strain of animal Bifidobacterium lactis subspecies with the effect of improving inflammatory bowel disease from milk base, and names it as animal Bifidobacterium lactis subspecies C-2 strain. The strain can regulate the intestinal environment, inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria, optimize the composition of intestinal microorganisms, thereby inducing anti-inflammatory response and improving intestinal barrier function. Therefore, the animal Bifidobacterium lactis subspecies C-2 strain can be used to prepare a medicine with the effect of preventing, improving or treating inflammatory bowel disease.

[0008] In a second aspect, the present invention provides a culture of Bifidobacterium animalis subsp. lactis C-2 as described in the first aspect, wherein the culture is prepared by the following method: inoculating Bifidobacterium animalis subsp. lactis C-2 into a culture medium and culturing at 35-38° C. for 22-26 h.

[0009] Among them, the above-mentioned "35-38℃" can be, for example, 35℃, 35.5℃, 36℃, 36.5℃, 37℃, 37.5℃, 38℃, etc. Other specific point values ​​within the numerical range can be selected, and they will not be described one by one here.

[0010] The above-mentioned "22-26 h" can be, for example, 22 h, 22.5 h, 23 h, 23.5 h, 24 h, 24.5 h, 25 h, 25.5 h, 26 h, etc. Other specific point values ​​within the numerical range can be selected, and they will not be described one by one here.

[0011] In a third aspect, the present invention provides a probiotic having the efficacy of improving inflammatory bowel disease, wherein the strain in the probiotic having the efficacy of improving inflammatory bowel disease comprises the Bifidobacterium animalis subsp. lactis C-2 strain described in the first aspect.

[0012] Preferably, in the probiotic, the viable count of the animal Bifidobacterium lactis subspecies C-2 is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, for example 1×10 9 CFU / mL (CFU / g), 2×10 9 CFU / mL (CFU / g), 5×10 9 CFU / mL (CFU / g), 8×10 9 CFU / mL (CFU / g), 1×10 10 CFU / mL (CFU / g), 5×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0013] Preferably, the strains in the probiotics having the effect of improving inflammatory bowel disease also include Lactobacillus gasseri Lactobacillus gasseri CKCC 1913, the deposit number is CGMCC No. 23175, and the deposit date is August 23, 2021.

[0014] The present invention also creatively discovered that the above-mentioned Lactobacillus gasseri Lactobacillus gasseri CKCC 1913 strain can bind to Bifidobacterium animalis subsp. Bifidobacterium animalis subsp. lactis The C-2 strain is compounded for the prevention, improvement or treatment of inflammatory bowel disease, and has a better effect than a single bacterial agent or other compound methods, indicating that CKCC 1913 and C-2 bacteria have a synergistic effect in regulating the balance of intestinal flora, inducing anti-inflammatory response to improve intestinal barrier function, etc.

[0015] Preferably, the ratio of the viable counts of animal Bifidobacterium lactis subspecies C-2 and Lactobacillus gasseri CKCC 1913 is 1:10-10:1, for example, it can be 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 5:1, 6:1, 8:1, 10:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described one by one here.

[0016] Preferably, the dosage form of the probiotic includes lyophilized powder, capsule, tablet or granule.

[0017] Preferably, the probiotic further comprises a protective agent.

[0018] Preferably, the protective agent comprises any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0019] In a fourth aspect, the present invention provides a use of the animal Bifidobacterium lactis subsp. C-2 as described in the first aspect, the culture as described in the second aspect, or the probiotic agent as described in the third aspect in the preparation of a product for regulating the intestinal microecological environment.

[0020] In a fifth aspect, the present invention provides a use of the animal Bifidobacterium lactis subsp. C-2 as described in the first aspect, the culture as described in the second aspect, or the probiotic agent as described in the third aspect in the preparation of a preparation having the efficacy of preventing, improving or treating inflammatory bowel disease.

[0021] Compared with the prior art, the present invention has the following beneficial effects: The present invention separates and preserves a new strain of animal Bifidobacterium lactis subspecies with the effect of improving inflammatory bowel disease from milk base, and names it as animal Bifidobacterium lactis subspecies C-2 strain. The strain can regulate the intestinal environment, inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria, optimize the composition of intestinal microorganisms, thereby inducing anti-inflammatory response and improving intestinal barrier function. Therefore, the animal Bifidobacterium lactis subspecies C-2 strain can be used to prepare a medicine with the effect of preventing, improving or treating inflammatory bowel disease.

[0022] The classification of the C-2 strain involved in the present invention is named Bifidobacterium animalis subsp. lactis The depository is Guangdong Microbiological Culture Collection Center, the deposit number is GDMCC No: 65455, the deposit date is November 8, 2024, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou; The CKCC 1913 strain involved in the present invention is classified as Lactobacillus formatus Lactobacillus gasseri The depository is the General Microbiology Center of China Microorganism Culture Collection Administration, the deposit number is CGMCC No. 23175, the deposit date is August 23, 2021, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the statistical result of the weight change rate of each group of mice; Figure 2This is a statistical result graph of the levels of various cytokines in the colon samples of each group of mice; Figure 3 It is the statistical result diagram of the content level of each cytokine in the serum samples of each group of mice; Figure 4 It is a statistical result diagram of the content level of each key sticky protein in the colon samples of each group of mice; Figure 5 This is a statistical graph of the concentration levels of various immunoglobulins in the serum samples of each group of mice. DETAILED DESCRIPTION

[0024] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0025] The following bacterial species information is: ① The classification and nomenclature of the C-2 strain involved in the following examples are Bifidobacterium animalis subsp. lactis , the deposit number is GDMCC No: 65455; ② The CKCC 1913 strain involved in the following examples is classified and named as Lactobacillus gasseri Lactobacillus gasseri , the deposit number is CGMCC No. 23175; ③ The ATCC 700541 involved in the following examples is the strain Bifidobacterium animalis subsp. lactis ATCC 700541.

[0026] The culture medium and its formula involved below are: ① MRS liquid medium: beef extract 10.0 g, glucose 20.0 g, peptone 10.0 g, yeast extract 5.0 g, sodium chloride 5.0 g, diammonium hydrogen citrate 2.0 g, dipotassium hydrogen phosphate 2.0 g, magnesium sulfate 0.2 g, manganese sulfate 0.05 g, Tween-80 1.0 g, distilled water to 1000 mL, pH 6.2-6.4.

[0027] MRS solid medium: beef extract 10.0 g, glucose 20.0 g, peptone 10.0 g, yeast extract 5.0 g, sodium chloride 5.0 g, diammonium hydrogen citrate 2.0 g, dipotassium hydrogen phosphate 2.0 g, magnesium sulfate 0.2 g, manganese sulfate 0.05 g, Tween-80 1.0 g, 2% agar powder, distilled water to 1000 mL, pH 6.2-6.4.

[0028] ② TPY liquid medium: weigh 26.4 g of commercially available TPY medium powder and dilute to 1000 mL with distilled water. TPY solid medium: weigh 26.4 g of commercially available TPY medium powder, dilute to 1000 mL with distilled water, and add 2% agar powder.

[0029] The simulated gastric fluid (pH 3.0) involved in the following embodiments is prepared by preparing 0.85% physiological saline, adjusting the pH to 3.0 with dilute hydrochloric acid, then adding 0.3% pepsin, and filtering and sterilizing with a microporous filter membrane after fully dissolving.

[0030] The preparation method of bacterial suspension and bacterial powder involved below is: after activating the strain, inoculate it into culture medium for cultivation to obtain culture solution; centrifuge the culture solution, resuspend the bacteria to obtain bacterial suspension, or further add protective agent for freeze drying to obtain freeze-dried bacterial powder product. Example 1

[0031] In this example, a strain of Bifidobacterium animalis subsp. lactis having the efficacy of improving inflammatory bowel disease was isolated and screened, and the steps were as follows: (1) Select samples separated from milk base, use 0.9% saline for 10-fold gradient dilution, dilute three times, spread on solid culture medium, culture at 37℃ for 48 h, pick out colonies of different morphologies, and purify them by streaking on the surface of modified MRS solid culture medium. Pick out single colonies and expand them in liquid culture medium at 37℃, and then preserve them in 35% glycerol. Example 2

[0032] In this example, the strains screened in Example 1 were subjected to morphological identification and 16S rRNA molecular biological identification, and the steps were as follows: (1) Morphological identification: The strain was inoculated into TPY medium, cultured anaerobically at 37°C for 48 h, and then observed under a microscope. After smear and Gram staining, it was observed that the Gram staining was positive, the strain morphology was polymorphic, milky white, 0.1-0.2 cm in diameter, with a smooth, moist, raised surface and neatly edged colonies.

[0033] (2) 16S rRNA molecular biological identification: The strain stored at -80℃ was taken out and inoculated into a centrifuge tube containing 20 mL TPY liquid medium at a ratio of 2% (v / v). After culturing at 37℃ for 24 h, it was centrifuged and centrifuged at 8000 rpm for 10 min. The supernatant was removed and the bacteria were collected. The genome of the strain was extracted, and bacterial universal primers were added for PCR amplification. The amplified product was sent to a sequencing company for sequencing identification. The strain was sequenced and analyzed, and its 16S rRNA sequence was shown in SEQ ID No: 1. The sequence obtained by sequencing was compared with the nucleic acid sequence in GeneBank, and the results showed that the strain was animal Bifidobacterium lactis subsp.

[0034] SEQ ID No: 1: .

[0035] Based on the results of 16S rRNA molecular biological identification and morphological identification in Example 2, it was confirmed that the strain belonged to Bifidobacterium animalis subsp. lactis and was named Bifidobacterium animalis subsp. lactis Bifidobacterium animalis subsp. lactis C-2 strain.

[0036] Test Example 1 This test case explores the effect of the C-2 strain on various symptom indicators of enteritis mice. The specific steps are as follows: (1) Experimental animals: 6-week-old SPF male Balb / C mice, housed in an environment with a temperature of 25°C, a humidity of 50%, and lighting for 12 h. They were fed with a basic mouse diet for one week (with free access to food and water).

[0037] (2) Grouping: After the adaptability test, the mice were randomly divided into 9 groups: S1 (C-2 bacterial suspension), S2 (CKCC 1913 bacterial suspension), S3 (C-2 bacterial suspension + CKCC 1913 bacterial suspension, the ratio of live bacteria was 10:1), S4 (C-2 bacterial suspension + CKCC 1913 bacterial suspension, the ratio of live bacteria was 1:1), S5 (C-2 bacterial suspension + CKCC 1913 bacterial suspension, the ratio of live bacteria was 1:10), S6 (ATCC700541 bacterial suspension + CKCC 1913 bacterial suspension, the ratio of live bacteria was 10:1), S7 was the positive control group (0.01 g / ml 5-ASA solution), S8 was the model group, and S9 was the blank group. There were 12 mice in each group. The total number of live bacteria in groups S1 to S6 was 1×10 9 CFU / mL.

[0038] (3) Intervention methods: During the experiment, mice in each group had free access to food and water.

[0039] On days 0-14, the S1-S6 groups were gavaged with 200 μL of the corresponding bacterial suspension, the S7 group was gavaged with 200 μL of 5-ASA solution, and the S8-S9 groups were gavaged with an equal volume of normal saline, once a day, 200 μL each time; On days 8–14, the drinking water of mice in groups S1–S8 was replaced with 2.5% DSS aqueous solution; On the 15th day, the mice were killed and blood was collected from their eyeballs. The blood samples were allowed to stand for 30 min and then centrifuged to collect serum samples. Colon tissue and intestinal content samples were also collected for detection and analysis of relevant indicators.

[0040] (a) Weight changes On the 14th day of the experiment, the mice in each group were weighed, and the weight change rate of the mice was calculated using the following formula, and the average value was taken as follows: Figure 1 shown.

[0041] Weight change rate = [(mouse weight on day N - mouse weight on day 0) / mouse weight on day 0] × 100% From the statistical results in the figure, we can see that both C-2 and CKCC 1913 strains can delay and weaken the weight loss of enteritis mice, and the C-2 bacterial suspension has the best effect. In addition, it was unexpectedly found that when C-2 and CKCC 1913 strains are used in combination, the effect of delaying and weakening the weight loss of enteritis mice is better.

[0042] (b) Changes in Disease Activity Index (DAI) The defecation of mice in each group was observed, and the DAI score of mice in each group was performed according to the scoring criteria in Table 1. The scoring results are shown in Table 2.

[0043] Table 1

[0044] Table 2

[0045] The data in the table show that compared with the S9 control group mice, the DAI scores of the S8 model group mice were significantly increased. The C-2 and CKCC 1913 strains can alleviate the symptoms of colitis such as weight loss, diarrhea, and bloody stools, and the C-2 bacterial suspension has the best effect. In addition, it was unexpectedly found that when the C-2 and CKCC 1913 strains were used in combination, the relevant effect was better.

[0046] (c) Inhibitory effect on inflammatory response The colon homogenate of each group of mice was collected and centrifuged, the supernatant was collected, and the mouse serum was collected. The colon homogenate and serum samples were tested according to the steps in the ELISA kit instructions, and the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and interleukin-10 (IL-10) in the collected cell supernatant and serum were detected respectively. The experimental results were analyzed by data processing software. The statistical results of the content levels of various cytokines in the colon samples are shown in Figure 2. Figure 2 The statistical results of the levels of various cytokines in serum samples are shown in Figure 3 shown.

[0047] The results in the figure show that compared with the S9 control group mice, the mRNA expression levels of pro-inflammatory cytokines TNF-α and IL-1β in the colon tissue and serum of the S8 model group mice were significantly increased, the expression level of pro-inflammatory cytokine IL-6 was also increased, and the mRNA expression level of anti-inflammatory factor IL-10 was reduced. Both C-2 and CKCC 1913 strains have anti-inflammatory effects, and the C-2 bacterial suspension has the best effect. In addition, it was unexpectedly found that when C-2 and CKCC 1913 strains are used in combination, the relevant effect is better.

[0048] (d) Changes in key colonic viscous proteins The qRT-PCR method was used to perform immunohistochemical analysis on the supernatant of mouse colon homogenate to detect the changes in the mRNA expression of four proteins: Claudin, Occludin, Zonula occludens-1 (ZO-1), and Mucin-2 (MUC2). Figure 4 shown.

[0049] The results in the figure show that compared with the S9 control group mice, the mRNA expression levels of four key sticky proteins, Claudin, Occludin, ZO-1, and MUC2, in the colon tissue of the S8 model group mice were significantly reduced. Both C-2 and CKCC 1913 strains can promote the expression of relevant key sticky proteins in the colon, and the C-2 bacterial suspension has the best effect. In addition, it was unexpectedly found that when C-2 and CKCC 1913 strains are used in combination, the relevant effect is better.

[0050] (e) Changes in serum immunoglobulin expression levels ELISA kits were used to detect the levels of immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) in the serum of each group of mice. The test results are shown in Figure 5 shown.

[0051] The results in the figure show that compared with the S9 control group mice, the expression levels of the three immunoglobulins Ig A, IgG, and Ig M in the serum of the S8 model group mice were significantly reduced. Both C-2 and CKCC 1913 strains can promote the expression of related immunoglobulins, and the C-2 bacterial suspension has the best effect. In addition, it was unexpectedly found that when the C-2 and CKCC 1913 strains were used in combination, the relevant effect was better.

[0052] In summary, the present invention has isolated and preserved a new strain of animal bifidobacterium with the effect of improving inflammatory bowel disease, which is named animal bifidobacterium lactis subspecies C-2 strain. The strain can regulate the intestinal environment, inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria, optimize the composition of intestinal microorganisms, thereby inducing anti-inflammatory response and improving intestinal barrier function. Therefore, this animal bifidobacterium lactis subspecies C-2 strain can be used to prepare a drug with the effect of preventing, improving or treating inflammatory bowel disease.

[0053] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0054] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0055] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. An animal Bifidobacterium lactis subspecies C-2 having the effect of improving inflammatory bowel disease, characterized in that: The classification of the Bifidobacterium animalis subspecies C-2 is named Bifidobacterium animalis subsp. lactis , the deposit number is GDMCC No: 65455, and the deposit date is November 8, 2024.

2. A culture of Bifidobacterium animalis subsp. lactis C-2 as claimed in claim 1, characterized in that The culture is prepared by the following method: Bifidobacterium animalis subspecies lactis C-2 is inoculated into a culture medium and cultured at 35-38° C. for 22-26 hours.

3. A probiotic agent having the effect of improving inflammatory bowel disease, characterized in that: The strain in the probiotic having the efficacy of improving inflammatory bowel disease includes the Bifidobacterium animalis subsp. lactis C-2 strain as claimed in claim 1.

4. The probiotic agent having the effect of improving inflammatory bowel disease according to claim 3, characterized in that: In the probiotic, the viable count of the animal Bifidobacterium lactis subspecies C-2 is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.

5. The probiotic agent having the effect of improving inflammatory bowel disease according to claim 3, characterized in that: The strains in the probiotics with the effect of improving inflammatory bowel disease also include Lactobacillus gasseri Lactobacillus gasseri CKCC1913, the deposit number is CGMCC No. 23175, and the deposit date is August 23, 2021.

6. The probiotic agent having the effect of improving inflammatory bowel disease according to claim 5, characterized in that: The ratio of the live bacteria count of Bifidobacterium animalis subspecies lactis C-2 to Lactobacillus gasseri CKCC 1913 is 1:10-10:

1.

7. The probiotic agent having the effect of improving inflammatory bowel disease according to claim 3, characterized in that: The dosage form of the probiotics includes freeze-dried powder, capsules, tablets or granules.

8. The probiotic agent having the effect of improving inflammatory bowel disease according to claim 3, characterized in that: The probiotics also include a protective agent; The protective agent includes any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

9. Use of the animal Bifidobacterium lactis subsp. C-2 according to claim 1 or the culture according to claim 2 or the probiotic according to any one of claims 3 to 8 in the preparation of a product for regulating intestinal microecological environment.

10. Use of the animal Bifidobacterium lactis subsp. C-2 according to claim 1, the culture according to claim 2, or the probiotic according to any one of claims 3 to 8 in the preparation of a preparation having efficacy in preventing, improving or treating inflammatory bowel disease.

Images